SequelSEC

Bionano Genomics, Inc. BNGO

Laboratory Analytical Instruments · CIK 0001411690 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$8.17M
Fiscal year ended 2026-06-30
Operating income
-$7.22M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Bionano Genomics, Inc. (BNGO) reported revenue of $8.17M and net income of -$7.42M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Bionano Genomics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

Bionano Genomics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$8.17M$6.69M$7.95M$7.37M$6.73M$6.46M$8.16M$6.07M$7.77M$8.77M
Cost of revenue$3.86M$3.44M$4.55M$4.00M$3.26M$3.52M$4.75M$14.52M$5.19M$5.94M
Gross profit$4.31M$3.25M$3.40M$3.37M$3.48M$2.94M$3.42M-$8.45M$2.58M$2.82M
Operating income-$7.22M-$7.90M-$8.54M-$8.54M-$7.80M-$8.46M-$11.94M-$43.90M-$17.02M-$31.12M
Net income-$7.42M-$8.30M-$7.93M-$8.50M-$6.86M-$3.10M-$20.12M-$44.25M-$16.22M-$31.42M
Research & development$2.99M$3.14M$3.23M$2.84M$2.93M$2.37M$3.47M$4.72M$6.83M$9.78M
Weighted-average diluted sharesshares 11.55Mshares 10.98MUnavailableshares 5.34Mshares 3.44Mshares 2.69MUnavailableshares 1.43Mshares 1.13MUnavailable
Pretax income-$7.42M-$8.29M-$7.90M-$8.49M-$6.85M-$3.10M-$20.12M-$44.22M-$16.20M-$31.44M
Income tax expense$7.00K$10.00K$35.00K$14.00K$10.00K$7.00K$1.00K$24.00K$26.00K-$18.00K
Diluted EPS$-0.64$-0.76Unavailable$-1.59$-1.99$-1.15Unavailable$-30.92$-14.41$-35.75
Selling, general & administrative$8.54M$8.01M$8.71M$9.06M$8.35M$9.03M$11.75M$9.46M$11.56M$19.09M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Bionano Genomics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$3.73M$3.42M$2.99M$3.06M$3.56M$3.62M$9.17M$8.79M$10.42M$15.76M
Total assets$47.59M$64.80M$73.58M$79.06M$76.01M$78.41M$76.67M$87.36M$129.36M$158.00M
Current assets$24.88M$38.98M$45.39M$48.80M$42.66M$44.93M$39.49M$46.98M$60.57M$85.61M
Total liabilities$15.98M$27.34M$29.16M$29.26M$30.64M$30.23M$41.30M$38.49M$49.03M$75.22M
Current liabilities$10.04M$21.23M$22.94M$22.98M$24.18M$26.41M$37.34M$32.95M$37.18M$58.51M
Total equity incl. NCI$31.61M$37.46M$44.42M$49.80M$45.37M$48.19M$35.38M$48.86M$80.34M$82.77M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$7.02M$7.69M$7.83M$8.42M$10.31M$11.42M$13.28M$16.28M$23.15M$23.80M
Accounts receivable$4.37M$4.13M$5.20M$4.53M$3.49M$3.35M$4.75M$5.32M$6.26M$8.31M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.56M$5.06M$5.59M$5.99M$6.24M$6.56M$6.96M$8.70M$8.73M$9.84M

Cash flow

Bionano Genomics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$4.67M-$5.72M-$4.18M-$5.92M-$3.49M-$2.76M-$6.50M-$13.31M-$20.98M-$28.13M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$13.68M$5.46M$4.01M-$4.67M$1.98M-$14.07M$3.00M-$5.38M$28.63M$47.59M
Financing cash flow-$9.69M$657.00K$1.60M$10.08M$1.47M$10.89M$3.89M$6.02M-$1.98M-$21.62M
Net change in cash-$681.00K$403.00K$1.44M-$497.00K-$63.00K-$5.95M$379.00K-$12.64M$5.67M-$2.19M
Stock-based compensation$970.00K$670.00K$926.00K$941.00K$1.08M$1.59M$1.94M$2.20M$2.58M$3.02M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$2.30M$2.31M$2.34M$2.38M$2.38M$2.43M$2.40M$5.63M$2.99M$3.01M

Derived

Bionano Genomics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin52.8%48.6%42.7%45.7%51.6%45.5%41.9%-139.1%33.3%32.2%
Operating margin-88.3%-118.1%-107.4%-115.9%-115.8%-131.1%-146.3%-722.9%-219.0%-354.9%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue11.9%10.0%11.6%12.8%16.0%24.6%23.7%36.3%33.2%34.4%
Current ratio2.48x1.84x1.98x2.12x1.76x1.70x1.06x1.43x1.63x1.46x
Revenue YoY growth21.4%3.6%-2.6%21.3%-13.4%-26.4%-23.9%-34.8%-10.3%18.3%
Net margin-90.8%Unavailable-99.8%-115.4%-101.8%Unavailable-246.5%-728.6%UnavailableUnavailable
R&D / revenue36.6%46.9%40.6%38.6%43.5%36.7%42.6%77.7%87.9%111.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BNGO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.